Navigation Links
Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
Date:11/4/2008

HAE: TSX

MONTREAL, Nov. 4 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE) announced today that Joseph Galli, Chairman and Chief Executive Officer of Haemacure, will present at the Rodman and Renshaw Annual Global Investor Conference being held November 10-12 in New York. Mr. Galli will present a corporate progress report, including an update on the Company's lead product candidate, Hemaseel(R)HMN (fibrin sealant). The Haemacure presentation is scheduled to begin at 3:15 p.m. local time on Monday, November 10th.

The Haemacure presentation will be webcast live and may be accessed by clicking on the following link: http://www.wsw.com/webcast/rrshq14/hae.cn. The presentation will also be available on the Haemacure website, http://www.haemacure.com, for a limited time following the conference.

Additional information on the Rodman and Renshaw Annual Global Investor Conference is available at http://www.rodmanandrenshaw.com/conferences.

Please visit the site at least five minutes prior to start time for instructions.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first half of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on the use of its fibrin sealant in adhesion prevention, aesthetics, combination with biomaterials, drug delivery, regenerative medicine, skin graft fixation for burn injuries, and wound management. Haemacure has discovered eleven additional specialty proteins and enzymes in one of its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure is headquartered in Montreal, Quebec and operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.


'/>"/>
SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
3. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
4. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
5. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
6. Haemacure Reports on its annual general and special meeting of shareholders
7. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
8. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
9. Haemacure financing receives shareholder consent - Series B Warrants are amended
10. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... January is National Stalking Awareness Month (NSAM), now in ... the corners and commit the crime of stalking, a very real danger to many in ... overlooked factor in stalking and other crimes. , “Stalking: know it. Name it. Stop it.”—so ...
(Date:1/17/2017)... ... , ... Anesthesia Progress – Everyone wants less pain during dental ... for each patient. Dentists have several general anesthesia alternatives and finding the right option ... Tokyo Dental College in Tokyo, Japan wanted to find out which anesthetic was the ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Gym Source, ... of a new showroom at South Dixie Hwy in Miami, FL. , “We are ... Gym Source. “The new innovative in-store concept is designed to give clients a seamless ...
(Date:1/17/2017)... ... January 17, 2017 , ... In the ... Activewear is a stand-out company for several differences from other mainstream brands. ... on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . It allows ...
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017 Precision ... and for the treatment of disease. The approach ... response to a therapy. The approach studies the ... their lifestyle and environment. In January 2015, Precision ... medicine to all diseases with more than one ...
(Date:1/17/2017)... , Jan. 17, 2017 North America Insulin ... new report, "North America Insulin Delivery Market Outlook to ... Insulin Delivery market. The report provides value, in millions ... (USD) within market segments - Insulin Pens, Insulin Pumps, ... report also provides company shares and distribution shares data ...
(Date:1/17/2017)... 17, 2017 Secretary of Health Dr. ... Gary Tennis are warning Pennsylvanians of the ... overdose deaths from the drug in Beaver ... to sedate large animals and is not meant for ... into contact with it," Secretary Murphy said. "It,s absolutely ...
Breaking Medicine Technology: